arrow
B

Beatriz Cuevas

hospital universitario de burgos
H指数:17
被引数:931

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

JAK抑制剂时代骨髓纤维化的生存结局与治疗模式

2026-08-210
PREAI
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia

突变谱和心血管风险因素对三阴性原发性血小板增多症预后的影响

Leukemia
IF13.4
2026-07-130
OAAI
Impact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma

CYP和ABCB1基因多态性对硼替佐米诱导的多发性骨髓瘤不良事件的影响

2026-04-040
OAAI
Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia

CALR突变型原发性血小板增多症的分子特征与治疗反应及预后

2026-03-230
OAAI
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study

共存骨髓增殖性肿瘤和淋巴性肿瘤:一项欧洲多中心回顾性研究

2025-10-170
OAAI
Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

根据Ipset分层,对原发性血小板增多症患者一线羟基脲治疗反应的预后价值

BLOOD
IF23.1
2024-11-050
PRE
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
LEUKEMIA
IF13.4
2024-09-270
PRE
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
LEUKEMIA
IF13.4
2024-08-300
PRE
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (vol 12, 13057, 2022)
2024-03-280
OAAI
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
2024-03-201
OAAI
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
2024-01-303
OAAI
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study

DNMT3A/TET2/ASXL1突变是真性红细胞增多症患者中与年龄无关的血栓形成危险因素: 一项观察性研究

2024-01-305
OAAI
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
2023-08-017
OAAI
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
2023-01-0110
OAAI
Breakthrough infections in MPN-COVID vaccinated patients
2022-11-150
OAAI
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (vol 101, 2231, 2022)
2022-10-200
OA
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
2022-09-277
OAAI
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
2022-08-309
OAAI
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

阿希替尼对帕马替尼预处理的慢性粒细胞白血病患者安全性和有效性的真实分析

2022-08-2318
OAAI